LexaGene Competitors

LexaGene (CVE:LXG) and Akumin (TSE:AKU) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, institutional ownership and risk.

Analyst Ratings

This is a summary of recent ratings and price targets for LexaGene and Akumin, as provided by MarketBeat.com.

Akumin has a consensus target price of C$4.25, suggesting a potential upside of 8.97%. Given Akumin's higher probable upside, analysts clearly believe Akumin is more favorable than LexaGene.

Profitability

This table compares LexaGene and Akumin's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares LexaGene and Akumin's gross revenue, earnings per share and valuation.

LexaGene has higher earnings, but lower revenue than Akumin. Akumin is trading at a lower price-to-earnings ratio than LexaGene, indicating that it is currently the more affordable of the two stocks.

Summary

Akumin beats LexaGene on 3 of the 5 factors compared between the two stocks.

SQI Diagnostics (CVE:SQD) and LexaGene (CVE:LXG) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, profitability, valuation, analyst recommendations, institutional ownership, earnings and risk.

Profitability

This table compares SQI Diagnostics and LexaGene's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares SQI Diagnostics and LexaGene's revenue, earnings per share and valuation.

LexaGene has lower revenue, but higher earnings than SQI Diagnostics. SQI Diagnostics is trading at a lower price-to-earnings ratio than LexaGene, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current recommendations for SQI Diagnostics and LexaGene, as reported by MarketBeat.com.

Summary

SQI Diagnostics beats LexaGene on 2 of the 3 factors compared between the two stocks.

Sernova (CVE:SVA) and LexaGene (CVE:LXG) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.

Profitability

This table compares Sernova and LexaGene's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Sernova and LexaGene, as reported by MarketBeat.

Earnings and Valuation

This table compares Sernova and LexaGene's revenue, earnings per share and valuation.

Sernova is trading at a lower price-to-earnings ratio than LexaGene, indicating that it is currently the more affordable of the two stocks.

GeneNews (TSE:GEN) and LexaGene (CVE:LXG) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, risk, institutional ownership, profitability, analyst recommendations and valuation.

Earnings and Valuation

This table compares GeneNews and LexaGene's top-line revenue, earnings per share (EPS) and valuation.

LexaGene has lower revenue, but higher earnings than GeneNews. LexaGene is trading at a lower price-to-earnings ratio than GeneNews, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and price targets for GeneNews and LexaGene, as provided by MarketBeat.

Profitability

This table compares GeneNews and LexaGene's net margins, return on equity and return on assets.

Summary

GeneNews beats LexaGene on 3 of the 3 factors compared between the two stocks.

LED Medical Diagnostics (CVE:LMD) and LexaGene (CVE:LXG) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, dividends and earnings.

Profitability

This table compares LED Medical Diagnostics and LexaGene's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares LED Medical Diagnostics and LexaGene's gross revenue, earnings per share and valuation.

LexaGene has lower revenue, but higher earnings than LED Medical Diagnostics. LED Medical Diagnostics is trading at a lower price-to-earnings ratio than LexaGene, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent recommendations for LED Medical Diagnostics and LexaGene, as reported by MarketBeat.

Summary

LED Medical Diagnostics beats LexaGene on 2 of the 3 factors compared between the two stocks.

LexaGene (CVE:LXG) and VentriPoint Diagnostics (CVE:VPT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, valuation, risk, institutional ownership, analyst recommendations, earnings and profitability.

Profitability

This table compares LexaGene and VentriPoint Diagnostics' net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent ratings for LexaGene and VentriPoint Diagnostics, as reported by MarketBeat.

Valuation and Earnings

This table compares LexaGene and VentriPoint Diagnostics' gross revenue, earnings per share (EPS) and valuation.

LexaGene has higher earnings, but lower revenue than VentriPoint Diagnostics. VentriPoint Diagnostics is trading at a lower price-to-earnings ratio than LexaGene, indicating that it is currently the more affordable of the two stocks.

Summary

VentriPoint Diagnostics beats LexaGene on 2 of the 3 factors compared between the two stocks.